Nicotine / Smoking Paradox in UC
The vault previously logged nicotine only as anecdote (carnivore/nicotine forum reports; see community-watchlist). It deserves a higher tier: UC is famously a disease of non-smokers/ex-smokers, and transdermal nicotine has genuine randomized-trial evidence for inducing improvement in active disease — while notably failing as maintenance therapy. This makes nicotine a real mechanistic clue about autonomic/mucus/barrier control, not a treatment recommendation.
Evidence level: moderate for induction, negative for maintenance. Safety: this is not an endorsement of smoking or self-medicating. Nicotine has cardiovascular and addiction risk and belongs on a clinician-discussion list only.
What the controlled evidence shows
According to PubMed:
- Sandborn et al., Ann Intern Med 1997 — transdermal nicotine (≤22 mg/day) for 4 weeks in mildly-to-moderately active UC: clinical improvement in 39% (12/31) vs 9% (3/33) placebo (P=0.007). Side effects (contact dermatitis, nausea; one acute pancreatitis) were dose-limiting. DOI
- Thomas et al., NEJM 1995 — transdermal nicotine as maintenance therapy over 6 months: no better than placebo at preventing relapse, with more premature withdrawals for side effects. DOI
The split is the key finding: nicotine appears to help active disease induction but not remission maintenance. Nicotine enema formulations have also been studied specifically for distal/left-sided disease, which is mechanistically relevant to a proctitis phenotype.
Why this matters for Paul’s model
Nicotine plausibly acts on several nodes already in central-theory:
- Mucus/barrier: nicotine can increase colonic mucin production — directly relevant to the mucus-reserve branch (mucus-phosphatidylcholine-barrier-uc).
- Autonomic/anti-inflammatory tone: the cholinergic anti-inflammatory pathway (vagal/α7-nicotinic) dampens cytokine output — overlapping the stress/autonomic branch in sleep-apnea-circadian-uc-barrier and pelvic-floor/autonomic notes in constipation-contact-time-pelvic-floor-uc.
- Distal delivery logic: the nicotine-enema literature reinforces the recurring theme that distal disease may respond to distal-targeted delivery.
The induction-vs-maintenance split is itself informative: it hints that nicotine relieves an acute barrier/inflammatory state without fixing the underlying persistence loop (see the persistence-loop note in central-theory).
Cautions / open questions
- Do not start smoking. The epidemiologic association is not a therapy; smoking’s harms dwarf any UC signal, and it worsens Crohn’s.
- Benefit is modest, short-term, and side-effect-limited; not a maintenance strategy.
- Open question: is a short, supervised transdermal or nicotine-enema trial ever appropriate as an adjunct for a refractory distal flare? Strictly a clinician conversation. Filed in key-open-questions.